Aetion is a health care analytics company that provides real-world evidence solutions for manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion delivers scientifically validated insights on the safety, effectiveness, and value of medical interventions through its core offering, the Aetion Evidence Platform.
The Aetion Evidence Platform analyzes large-scale real-world data—such as health records and claims data—to generate transparent and rapid answers that support critical decisions in health care. These insights inform product development, commercialization strategies, and payment models by helping stakeholders understand what works best, for whom, and when. The platform is designed for use by life sciences manufacturers, health care payers, and regulatory bodies who require robust evidence to guide medical and policy decisions.
Founded by Harvard Medical School faculty with decades of expertise in epidemiology and health outcomes research, Aetion differentiates itself through the scientific rigor and transparency of its analytics. The company is based in New York City and operates with a team of over 200 employees, supported by leading healthcare and technology investors.
How was Aetion started?
Aetion was founded by academic experts in epidemiology and health outcomes research, including Jeremy Rassen (Co-founder & CEO, epidemiologist and computer scientist), and Sebastian Schneeweiss (Co-Founder and Senior Advisor, physician and pharmacoepidemiologist). Their backgrounds in clinical science and data analytics underpin Aetion's focus on scientifically validated, real-world evidence for health care decision-making.
Who does Aetion serve?
Aetion primarily serves:
- Life sciences manufacturers seeking evidence for product development and regulatory approval
- Health care payers and purchasers evaluating treatment effectiveness and value
- Regulatory agencies requiring transparent and reliable data to inform health policy and safety decisions
While specific customers are not listed, Aetion's solutions are aimed at organizations that need validated real-world evidence in the medical and health care sectors.
What makes Aetion different?
Aetion stands out for its commitment to transparent, reproducible analytics and rapid evidence generation. The company’s leadership brings extensive expertise in epidemiology, data science, and health care technology, including:
- Jeremy Rassen (Co-founder & CEO)
- Kevin Riley (President)
- Nicolle Gatto (Chief Science Officer)
- Sebastian Schneeweiss (Co-Founder and Senior Advisor)
- Wendy Turenne (Chief Data Officer)
Their collective experience ensures that Aetion’s platform meets the high standards required for regulatory and clinical decision-making.
Who are Aetion's investors?
Aetion is backed by a range of prominent investors in healthcare and technology, including New Enterprise Associates (NEA), Warburg Pincus, Flare Capital Partners, Greenspring Associates, Lakestar, B Capital, Foresite Capital, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Johnson & Johnson Innovation—JJDC, UCB, Amgen Ventures, and Horizon Health Services, Inc. More about the company can be found on their About page.
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like Aetion and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.